Drug Approval | December 27, 2021
Covaxin receives approval for Emergency Use in Children 12-18 years
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
The Home Healthcare market is expected to be US $ 14.2 by 2025
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
Effectiveness of Covaxin against the Omicron variant is currently being studied
Subscribe To Our Newsletter & Stay Updated
